Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 232-237

  Yang, Wei ^a   Raufi, Alexander ^a   Klempner, Samuel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Gastric; Mutation; Proteomics; Sequencing; Targeted therapy

Indexed keywords

AFATINIB; AFLIBERCEPT; AXITINIB; BRIVANIB; CEDIRANIB; CETUXIMAB; DACOMITINIB; DOVITINIB; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; LAPATINIB; LUCITANIB; NIMOTUZUMAB; ONARTUZUMAB; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; POZIOTINIB; RAMUCIRUMAB; RILOTUMUMAB; SARACATINIB; TELATINIB; TEMSIROLIMUS; TRASTUZUMAB; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VORINOSTAT; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 4547; BEVACIZUMAB; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IPATASERTIB; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B;

ANTIANGIOGENIC ACTIVITY; CANCER MORTALITY; CANCER SURVIVAL; DRUG TARGETING; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HOMOZYGOSITY; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL FUNCTION; COLORECTAL CANCER; DNA DAMAGE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FUNCTIONAL PROTEOMICS; GASTRO ESOPHAGEAL JUNCTION CANCER; GENE OVEREXPRESSION; GENETIC DIFFERENCE; INOPERABLE CANCER; LOWER ESOPHAGUS SPHINCTER; MUTATION; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

CANCER; GASTRIC; MUTATION; PROTEOMICS; SEQUENCING; TARGETED THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DISCOVERY; GENES, ERBB; HUMANS; MOLECULAR TARGETED THERAPY; PROTEOMICS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84905253056     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.05.003     Document Type: Review

References (96)

1. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63(1):11-30.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965, 64:31-49.
4. Cunningham D., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006, 355(1):11-20.
5. Earle C.C., et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. Can. J. Surg. 2002, 45(6):438-446.
6. Group G., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303(17):1729-1737.
7. Macdonald J.S., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001, 345(10):725-730.
8. Smalley S.R., et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol. 2012, 30(19):2327-2333.
9. van Hagen P., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012, 366(22):2074-2084.
10. Cunningham D., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008, 358(1):36-46.
11. Waddell T., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14(6):481-489.
12. Koizumi W., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008, 9(3):215-221.
13. Koizumi W., et al. Addition of docetaxel to S- without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J. Cancer Res. Clin. Oncol. 2014, 140(2):319-328.
14. Sakuramoto S., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007, 357(18):1810-1820.
15. Schwarz R.E., Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur. J. Surg. Oncol. 2002, 28(3):214-219.
16. Strong V.E., et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann. Surg. 2010, 251(4):640-646.
17. Sasako M., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011, 29(33):4387-4393.
18. Bickenbach K., Strong V.E. Comparisons of gastric cancer treatments: east vs. west. J. Gastric Cancer 2012, 12(2):55-62.
19. Bang Y.J., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
20. Lordick F., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14(6):490-499.
21. Deng N., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61(5):673-684.
22. Zhang J., et al. The impact of next-generation sequencing on genomics. J. Genet. Genomics 2011, 38(3):95-109.
23. Grada A., Weinbrecht K. Next-generation sequencing: methodology and application. J. Invest. Dermatol. 2013, 133(8):e11.
24. Lee J., et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012, 7(6):e38892.
25. Dulak A.M., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 2013, 45(5):478-486.
26. Zang Z.J., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 2012, 44(5):570-574.
27. Dulak A.M., et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012, 72(17):4383-4393.
28. Lee J., Ou S.H. Towards the goal of personalized medicine in gastric cancer-time to move beyond HER2 inhibition. Part I: targeting receptor tyrosine kinase gene amplification. Discov. Med. 2013, 15(85):333-341.
29. Chong M.L., et al. Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. Int. J. Cancer 2014, 134(5):1232-1238.
30. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2(2):127-137.
31. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5(5):341-354.
32. Kim M.A., et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008, 52(6):738-746.
33. Langer R., et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J. Clin. Pathol. 2006, 59(6):631-634.
34. Okines A.F., et al. Biomarker analysis in oesophagogastric cancer: results from the REAL3 and TransMAGIC trials. Eur. J. Cancer 2013, 49(9):2116-2125.
35. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008, 19(9):1523-1529.
36. Yano T., et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 2006, 15(1):65-71.
37. Fujimoto-Ouchi K., et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol. 2007, 59(6):795-805.
38. Holbro T., et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(15):8933-8938.
39. Ocana A., et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J. Natl. Cancer Inst. 2013, 105(4):266-273.
40. Hayashi M., et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin. Cancer Res. 2008, 14(23):7843-7849.
41. Zhang X.L., et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J. Surg. 2009, 33(10):2112-2118.
42. Baselga J., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366(2):109-119.
43. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
44. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8(8):579-591.
45. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2(10):795-803.
46. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8(8):592-603.
47. Oh S.Y., et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008, 8:123.
48. Kim S.E., et al. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88-94.
49. Cabuk D., et al. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 2007, 72(1-2):111-117.
50. Juttner S., et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J. Clin. Oncol. 2006, 24(2):228-240.
51. Wadhwa R., et al. Gastric cancer-molecular and clinical dimensions. Nat. Rev. Clin. Oncol. 2013, 10(11):643-655.
52. Zhou Y., et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010, 31(6):549-558.
53. Hurwitz H.I., et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013, 18(9):1004-1012.
54. Shah M.A., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 2006, 24(33):5201-5206.
55. Ohtsu A., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2011, 29(30):3968-3976.
56. Shen L., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2014, (in press).
57. McCarty M.F., et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol. Cancer Ther. 2004, 3(9):1041-1048.
58. Jung Y.D., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of astric cancer in a nude mouse model. Eur. J. Cancer 2002, 38(8):1133-1140.
59. Fuchs C.S., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383(9911):31-39.
60. J. Clin. Oncol. 2014, 32(Suppl. 3). (abstr LBA7).
61. Matsumoto K., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer 2012, 106(4):727-732.
62. Su X., et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br. J. Cancer 2014, 110(4):967-975.
63. Xie L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013, 19(9):2572-2583.
64. Appleman L.J. MET signaling pathway: a rational target for cancer therapy. J. Clin. Oncol. 2011, 29(36):4837-4838.
65. Lennerz J.K., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 2011, 29(36):4803-4810.
66. Graziano F., et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J. Clin. Oncol. 2011, 29(36):4789-4795.
67. Smolen G.A., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(7):2316-2321.
68. Catenacci D.V., et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011, 1(7):573-579.
69. Shah M.A., et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013, 8(3):e54014.
70. Qi J., et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011, 71(3):1081-1091.
71. Danilkovitch-Miagkova A., Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 2002, 109(7):863-867.
72. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2(7):489-501.
73. Volinia S., et al. Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics 1994, 24(3):472-477.
74. Liu J.F., et al. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J. Gastroenterol. 2010, 16(39):4986-4991.
75. Bader A.G., Kang S., Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(5):1475-1479.
76. Velho S., et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 2005, 41(11):1649-1654.
77. Shi J., et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012, 12:50.
78. Shi J., et al. Frequent gene amplification predicts poor prognosis in gastric cancer. Int. J. Mol. Sci. 2012, 13(4):4714-4726.
79. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 2008, 18(1):73-79.
80. Klempner S.J., Myers A.P., Cantley L.C. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 2013, 3(12):1345-1354.
81. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 2009, 59(2):111-137.
82. Dong M., Phan A.T., Yao J.C. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin. Cancer Res. 2012, 18(7):1830-1836.
83. Ohtsu A., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J. Clin. Oncol. 2013, 31(31):3935-3943.
84. Bhattacharya B., et al. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biol. Ther. 2012, 13(1):34-42.
85. Mazzoletti M., et al. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res. 2011, 71(13):4573-4584.
86. She Q.B., et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3(8):e3065.
87. Lin J., et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin. Cancer Res. 2013, 19(7):1760-1772.
88. Yang W.S., et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. J. Proteome Res. 2012, 11(2):1078-1088.
89. Lam S.W., Jimenez C.R., Boven E. Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat. Rev. 2014, 40(1):129-138.
90. Chae Y.K., Gonzalez-Angulo A.M. Implications of functional proteomics in breast cancer. Oncologist 2014, 19(4):328-335.
91. Lin L.L., Huang H.C., Juan H.F. Discovery of biomarkers for gastric cancer: a proteomics approach. J. Proteomics 2012, 75(11):3081-3097.
92. Wu J.Y., et al. Discovery of tumor markers for gastric cancer by proteomics. PLoS One 2014, 9(1):e84158.
93. Torti D., et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int. J. Cancer 2012, 130(6):1357-1366.
94. Lee J., et al. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One 2013, 8(1):e54644.
95. Slotta-Huspenina J., et al. A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas. Br. J. Cancer 2013, 109(2):370-378.
96. Shan W., et al. A proprietary multianalyte test for predicting extreme resistance to neoadjuvant 5-FU based chemoradiation (CTRT) in esophageal adenocarcinoma (EC). J. Clin. Oncol. 2014, 32(suppl 3; abstr 51).